# US 2023/0053812 A1 · Stable peptide formulations for oral use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053812 A1
- Document ID: US20230053812A1
- Status: Published application
- Kind: A1
- Application number: 17/875,117
- Filed: 2022-07-27
- Published: 2023-02-23
- Earliest claimed: 2021-07-27
- Assignees: Aurobindo Pharma Ltd
- Applicants: Aurobindo Pharma Ltd
- Inventors: Saravanan KANNUSAMY; Prabhakaran CHAKKIRALA; Raghavendra Bharat GUNDA; Nagaprasad VISHNUBHOTLA; Meenakshisunderam SIVAKUMARAN
- Web page: https://patentgrep.com/patent/US20230053812A1

## CPC

- A61K 38/26: Glucagons
- A61K 9/009: {Sachets, pouches characterised by the material or function of the envelope (with gastric retention A61K9/0065; sachets which are not administered but function merely as a container are classified according to the content, e.g. sachets comprising powder for reconstitution of a drink A61K9/0095)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/401: Proline; Derivatives thereof, e.g. captopril
- A61K 38/095: Oxytocins; Vasopressins; Related peptides
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61K 38/23: Calcitonins
- A61K 38/28: Insulins
- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61K 38/31: Somatostatins
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to stable pharmaceutical formulation useful for the oral administration comprising a peptide or protein drug and a permeation enhancer. In particular, the invention relates to stabilized pharmaceutical formulations comprising GLP-1 receptor agonist such as Semaglutide and a permeation enhancer and its process for preparation.

## Claims

### Claim 1

A stable pharmaceutical formulation comprising peptide or protein drug and permeation enhancers other than sodium N-(8-(2-hydroxybenzoyl) amino)caprylate (SNAC).

### Claim 2 (depends on 1)

The stable pharmaceutical formulation as claimed in claim 1, wherein the peptide or protein drug is selected from the group comprising insulin, insulin aspart, insulin glulisine, insulin glargine, insulin detemir, NPH insulin, insulin degludec, insulin analog (e.g., a long acting basal insulin analog or a protease stabilized long acting basal insulin analog; exemplary insulin analogs include, without limitation, insulin lispro, insulin PEGIispro, GLP-1, a GLP-1 analog (e.g., an acylated GLP-1 analog or a diacylated GLP-1 analog) or GLP-1 agonist (also referred to as “glucagon-like peptide-1 receptor agonist” or “GLP-1 receptor agonist”), a GLP-2 agonist or analog (e.g., teduglutide or elsiglutide), amylin, an amylin analog, pramlintide, a somatostatin analog (e.g., octreotide, lanreotide, or pasireotide), desmopressin (e.g., desmopressin acetate), calcitonin (e.g., calcitonin-salmon), parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP).

### Claim 3 (depends on 1)

The stable pharmaceutical formulation as claimed in claim 1, wherein the permeation enhancers are selected from but not limited to soyabean lecithin, arginine, lysine, phenyl alanine, tryptophan, sodium caprylate, sodium caprate, capsaicin analogue 10-Hydroxy-N-[(4-hydroxy-3-methoxyphenyl) methyl] decanamide (Compound 14), sodium laurate, sodium chenodeoxycholate, propyl gallate, dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate, sucrose mono-tetradecanoate, sodium dodecyl sulfate, sodium hexanoate, sodium heptanoate, sodium octanoate, sodium nonanoate, sodium decanoate, sodium undecanoate, sodium dodecanoate, sodium tridecanoate, sodium tetradecanoate and combinations thereof.

### Claim 4 (depends on 2)

The stable pharmaceutical formulation as claimed in claim 2, wherein the GLP-1 receptor agonist is selected from the group comprising semaglutide, liraglutide, exenatide, exendin-4, lixisenatide, taspoglutide, albiglutide, dulaglutide, langlenatide, beinaglutide, efpeglenatide, coumaglutide and pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 1)

The stable pharmaceutical formulation as claimed in claim 1, wherein said formulation further comprises one or more excipients selected from diluent, disintegrant, binder, lubricant, alkalizing agent and anti-oxidant or combinations thereof.

### Claim 6 (depends on 1)

The stable pharmaceutical formulation as claimed in claim 1, wherein said formulation comprising a GLP-1 receptor agonist, permeation enhancers other than sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) comprising 40% to 98% w/w of the composition and one or more other excipients comprising 1% to 30% w/w of the composition.

### Claim 7 (depends on 6)

A method of preparing stable pharmaceutical formulation as claimed in claim 6, wherein said method comprising the steps of;
a) granulating a mixture comprising GLP-1 receptor agonist, permeation enhancers and other excipients such as diluent, disintegrant, binder, lubricant, alkalizing agent and anti-oxidant or combinations thereof.
b) compressing the granulate obtained in step a) into tablets and optionally adding further diluent and/or lubricant to the granulate prior to compression.

### Claim 8

A stable pharmaceutical formulation comprising semaglutide, permeation enhancers other than sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) comprising 40% to 98% w/w of the composition and one or more other excipients comprising 1% to 30% w/w of the composition.

### Claim 9 (depends on 8)

The stable pharmaceutical formulation as claimed in claim 8, wherein the pharmaceutical formulation comprises
a) semaglutide and
b) permeation enhancers selected from the group comprising soyabean lecithin, arginine, lysine, phenyl alanine, tryptophan, sodium caprylate, sodium caprate, capsaicin analogue 10-Hydroxy-N-[(4-hydroxy-3-methoxyphenyl) methyl] decanamide (Compound 14), sodium laurate, sodium chenodeoxycholate, propyl gallate, dodecyl maltoside, tridecyl maltoside, tetradecyl maltoside, sucrose mono-dodecanoate, sucrose mono-tridecanoate, sucrose mono-tetradecanoate, sodium dodecyl sulfate, sodium hexanoate, sodium heptanoate, sodium octanoate, sodium nonanoate, sodium decanoate, sodium undecanoate, sodium dodecanoate, sodium tridecanoate, sodium tetradecanoate and combinations thereof and wherein said permeation enhancers comprises at least or above 70 w/w % of the composition.

### Claim 10 (depends on 8)

A process for the preparation of stable pharmaceutical formulation of semaglutide as claimed in claim 8, wherein said process comprising;
a. co-sifting and mixing semaglutide, permeation enhancers and other excipients,
b. preparing binder solution by dissolving binder in the water,
c. granulating the mixture of step (a) with binder solution of step (b),
d. drying the granules of step (c),
e. adding the diluent and lubricant to blend of step (d) and compressing into tablet.
